Natera Stock Slides 3.55% on Revised Partnership as $300M Volume Ranks 345th in Market Activity

On September 23, 2025, , . The stock's performance followed a series of updates regarding its diagnostic pipeline and partnership developments, which reshaped investor sentiment in the biotech sector.

Recent corporate updates highlighted Natera's expansion of its non-invasive prenatal testing capabilities, . Analysts noted that while these technical advancements align with long-term strategic goals, .

Strategic collaborations also featured prominently in the news cycle, particularly a revised distribution agreement with a major European healthcare provider. , raising questions about near-term market penetration potential. .

Currently, the available back-testing tools are designed to work on a single ticker (or an index/ETF that already aggregates a basket of securities). Constructing and rebalancing a 500-stock, equal-weighted portfolio on a daily basis would require a cross-sectional engine that our present toolkit does not yet expose. To move forward, please let me know which of the following approaches best meets your needs: 1. Approximate the idea with an existing index/ETF (for example, . 2. Reduce the scope to a single security each day (e.g., . 3. Pause and wait until a multi-asset portfolio back-test module becomes available. 4. Another alternative you have in mind. Once you choose an option, .